BioSpace

Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial

Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.

By BioSpace

1 min read
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights